Relapsed and Refractory Multiple Myeloma Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Chemotherapy, Radiotherapy, Stem Cell Transplantation, Others), By Drug Class (Monoclonal Antibodies, Immunomodulatory Drugs, Proteasome Inhibitors, Steroids, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospitals, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region Forecast 2019-2030

Relapsed and Refractory Multiple Myeloma Treatment Market size was valued at US$ 22.0 billion in 2024 and is expected to reach US$ 30.1 billion by 2031, growing at a significant CAGR of 4.6% from 2025-2031. The increase in the prevalence of multiple myeloma. According to World Cancer Research Fund International 2012, approximately 114,000 multiple myeloma cases are observed around the world. According to Novartis data 2015, approximately 75,000 people are living with relapsed and refractory multiple myeloma around the globe.

Moreover, a strong product pipeline for relapsed and refractory multiple myeloma treatment is expected to boost the market. For instance, in April 2017, Genmab A/S announced that Janssen Research and Development LLC collaborated with the European Myeloma Network (EMN) to start a phase III study of daratumumab in combination with dexamethasone and pomalidomide in relapsed and refractory multiple myeloma. In addition, FDA approval for various drugs might upsurge the revenue of the market.

For instance, in January 2016, Amgen received FDA approval for a supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) injection in combination with lenalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma. Relapsed multiple myeloma occurs when the multiple myeloma disease or its signs and symptoms return after a period of improvement. Relapsed and Refractory Multiple Myeloma Treatment Market occurs when the disease is unresponsive to a primary therapy or it becomes unresponsive over time. Multiple myeloma or plasma cell myeloma, is a cancer of plasma cells, a type of WBC normally responsible for the production of antibodies. At the initial stage, there are no symptoms noticed with multiple myeloma,

However, in the advanced stage bleeding, bone pain, anemia, and frequent infections may occur. Risk factors for multiple myeloma are high consumption of alcohol and obesity. It may be caused by abnormal production of antibodies may cause renal problems and an increase in the thickness of blood. The disease can be considered treatable, but incurable. It can be treated with radiotherapy, chemotherapy, and stem cell transplantation among others.